Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359264 | 0.95 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL18254066 | 0.91 | HTT (0.81) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL2402780 | 0.90 | HTT (0.74) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9874334 | 0.90 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL15346534 | 0.90 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9340146 | 0.90 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL1299850 | 0.89 | HTT (0.72) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL14010423 | 0.89 | HTT (0.72) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL13055383 | 0.88 | LMNA (0.80) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6494174 | 0.87 | HTT (0.70) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-5883132-A | MULTISTAGE REACTION OF AMIDATION, ACTIVATION, COUPLING AND HYDROLYSIS | FOURNIER INDUSTRIE ET SANTE (FR) | 1999-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | HTT 3681/4885LMNA 2106/4885SMN1; SMN2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.